ARQT
Arcutis Biotherapeutics Inc
NASDAQ: ARQT · HEALTHCARE · BIOTECHNOLOGY
$21.24
-3.28% today
Updated 2026-06-05
Market cap
$3.05B
P/E ratio
—
P/S ratio
7.34x
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$13 – $32
Volume
1.6M
Arcutis Biotherapeutics Inc (ARQT) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$21.24
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$131.70
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.1B | $0.2B | $0.4B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -0.57%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.